Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7043093rdf:typepubmed:Citationlld:pubmed
pubmed-article:7043093lifeskim:mentionsumls-concept:C0450442lld:lifeskim
pubmed-article:7043093lifeskim:mentionsumls-concept:C0045052lld:lifeskim
pubmed-article:7043093pubmed:issue2lld:pubmed
pubmed-article:7043093pubmed:dateCreated1982-7-19lld:pubmed
pubmed-article:7043093pubmed:abstractTextThe hypertensiogenic effects of 19-hydroxyandrostenedione (19-OH-A-dione) reported previously to be an amplifier of the action of aldosterone were evaluated using the same experimental procedures as for DOCA-salt hypertension in rats. The 19-OH-A-dione treated rats developed high blood pressure, hypokalemia, suppressed plasma renin activity and low plasma aldosterone and corticosterone concentrations as the DOCA treated rats did. The results demonstrate that 19-OH-A-dione amplifies the action of endogenous aldosterone and causes a hypertensive state simulating mineralocorticoid excess. Amplifiers of the action of aldosterone are considered to work as hypertensinogenic agents in the presence of the adrenal cortex.lld:pubmed
pubmed-article:7043093pubmed:languageenglld:pubmed
pubmed-article:7043093pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7043093pubmed:citationSubsetIMlld:pubmed
pubmed-article:7043093pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7043093pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7043093pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7043093pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7043093pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7043093pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7043093pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7043093pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7043093pubmed:statusMEDLINElld:pubmed
pubmed-article:7043093pubmed:monthFeblld:pubmed
pubmed-article:7043093pubmed:issn0022-4731lld:pubmed
pubmed-article:7043093pubmed:authorpubmed-author:SekiharaHHlld:pubmed
pubmed-article:7043093pubmed:issnTypePrintlld:pubmed
pubmed-article:7043093pubmed:volume16lld:pubmed
pubmed-article:7043093pubmed:ownerNLMlld:pubmed
pubmed-article:7043093pubmed:authorsCompleteYlld:pubmed
pubmed-article:7043093pubmed:pagination329-31lld:pubmed
pubmed-article:7043093pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:7043093pubmed:meshHeadingpubmed-meshheading:7043093-...lld:pubmed
pubmed-article:7043093pubmed:meshHeadingpubmed-meshheading:7043093-...lld:pubmed
pubmed-article:7043093pubmed:meshHeadingpubmed-meshheading:7043093-...lld:pubmed
pubmed-article:7043093pubmed:meshHeadingpubmed-meshheading:7043093-...lld:pubmed
pubmed-article:7043093pubmed:meshHeadingpubmed-meshheading:7043093-...lld:pubmed
pubmed-article:7043093pubmed:meshHeadingpubmed-meshheading:7043093-...lld:pubmed
pubmed-article:7043093pubmed:meshHeadingpubmed-meshheading:7043093-...lld:pubmed
pubmed-article:7043093pubmed:meshHeadingpubmed-meshheading:7043093-...lld:pubmed
pubmed-article:7043093pubmed:meshHeadingpubmed-meshheading:7043093-...lld:pubmed
pubmed-article:7043093pubmed:meshHeadingpubmed-meshheading:7043093-...lld:pubmed
pubmed-article:7043093pubmed:meshHeadingpubmed-meshheading:7043093-...lld:pubmed
pubmed-article:7043093pubmed:year1982lld:pubmed
pubmed-article:7043093pubmed:articleTitle19-hydroxyandrostenedione as a new hypertensinogenic agent.lld:pubmed
pubmed-article:7043093pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7043093pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:7043093pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7043093lld:pubmed